BRUSSELS, BELGIUM -- (MARKET WIRE) -- September 25, 2006 -- UCB and sanofi-aventis announced today that they have entered into an agreement to co-promote in the United States the prescription antihistamine medicine, Xyzal® (levocetirizine dihydrochloride). Xyzal® is a once-daily antihistamine which was first launched in Europe in 2001 and currently marketed in 49 countries around the world where it enjoys leadership position in key markets.
